Case Studies on the Use of IO in NSCLC With Drs. Jeffrey Kern and Laurie Carr
MedEdTalks - Oncology
enJanuary 04, 2023
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk
enMay 10, 2021
What was the main topic of the podcast episode?
Summarise the key points discussed in the episode?
Were there any notable quotes or insights from the speakers?
Which popular books were mentioned in this episode?
Were there any points particularly controversial or thought-provoking discussed in the episode?
Were any current events or trending topics addressed in the episode?
About this Episode
Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.
Recent Episodes from MedEdTalks - Oncology
Updates on the Use of Neoadjuvant and Adjuvant IO in Patients With NSCLC With Drs. Laurie Carr and Heather Wakelee
MedEdTalks - Oncology
enJanuary 04, 2023
Updates in IO for Advanced NSCLC – Options for First-line Treatment and Management of Progressive Disease With Drs. Laurie Carr and Heather Wakelee
MedEdTalks - Oncology
enJanuary 04, 2023
NSCLC: Updates in Testing and Interpreting Results – Focus on IO With Drs. Laurie Carr and David Ross Camidge
MedEdTalks - Oncology
enJanuary 04, 2023
NSCLC: Optimizing Care Coordination – Through the Patient and Caregiver’s Eyes
MedEdTalks - Oncology
enJanuary 04, 2023
Lung Cancer Advances and Challenges During a Pandemic – Where Do We Go From Here? With Drs. Jeffrey Kern and Charu Aggarwal
MedEdTalks - Oncology
enJanuary 04, 2023
Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy With Drs. Howard Kaufman and Anna Pavlick
Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.
Mechanisms of Oncolytic Viral Therapy With Drs. Howard Kaufman and Kevin Harrington
Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.
Overview of Oncolytic Viral Therapy – Focus on Melanoma With Drs. Howard Kaufman and Dmitriy Zamarin
Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk
Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.